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Abstract
Background: Lats1 (large tumor suppressor 1) codes for a serine/threonine kinase that plays a
role in the progression through mitosis. Genetic studies demonstrated that the loss of LATS1 in
mouse, and of its ortholog wts (warts) in Drosophila, is associated with increased cancer incidence.
There are conflicting reports, however, as to whether overexpression of Lats1  inhibits cell
proliferation. CUX1 is a transcription factor that exists in different isoforms as a result of
proteolytic processing or alternative transcription initiation. Expression of p110 and p75 CUX1 in
transgenic mice increases the susceptibility to cancer in various organs and tissues. In tissue culture,
p110 CUX1 was shown to accelerate entry into S phase and stimulate cell proliferation.
Results: Genome-wide location arrays in cell lines of various cell types revealed that Lats1 was a
transcriptional target of CUX1. Scanning ChIP analysis confirmed that CUX1 binds to the
immediate promoter of Lats1. Expression of Lats1 was reduced in cux1-/- MEFs, whereas it was
increased in cells stably or transiently expressing p110 or p75 CUX1. Reporter assays confirmed
that the immediate promoter of Lats1 was sufficient to confer transcriptional activation by CUX1.
Lats1 was found to be overexpressed in tumors from the mammary gland, uterus and spleen that
arise in p110 or p75 CUX1 transgenic mice. In tissue culture, such elevated LATS1 expression did
not hinder cell cycle progression in cells overexpressing p110 CUX1.
Conclusion:  While inactivation of Lats1/wts  in mouse and Drosophila can increase cancer
incidence, results from the present study demonstrate that Lats1 is a transcriptional target of
CUX1 that can be overexpressed in tumors of various tissue-types. Interestingly, two other studies
documented the overexpression of LATS1 in human cervical cancers and basal-like breast cancers.
We conclude that, similarly to other genes involved in mitotic checkpoint, cancer can be associated
with either loss-of-function or overexpression of Lats1.
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Background
The large tumor suppressor (Lats)/Warts (wts) gene is con-
served from insect to humans and codes for a serine/thre-
onine kinase that was successively implicated as a tumor
suppressor, a regulator of mitosis and a key component of
the so-called Hippo pathway that controls the coordina-
tion between cell proliferation and apoptosis (reviewed in
[1,2]). Mutations in the Drosophila lats1 homolog, warts
(wts), were found originally to cause various developmen-
tal defects and dramatic overproliferation phenotypes
including the development of tumors in various tissues
[3,4]. Complementation assays in flies demonstrated that
the human LATS1  gene was able to suppress tumour
growth and rescue all developmental defects of wts
mutants including embryonic lethality [5]. Lats1-deficient
mice spontaneously developed non-metastatic ovarian
stromal cell tumours and metastatic large soft tissue sarco-
mas with a penetrance of 100% and 14%, respectively [6].
Loss-of-heterozygosity (LOH) of the LATS1 chromosomal
locus at 6q24-25.1 has been reported in a fraction of
human breast cancers and salivary duct carcinomas, but
inactivating point mutations have not been found [7,8].
Hypermethylation of the LATS1  gene promoter and
reduction in mRNA expression was documented in some
human breast cancers, soft tissue sarcomas and astrocyto-
mas [9-11].
No substrate of LATS1 was known until the hippo path-
way was deciphered and a downstream transcriptional
effector was identified. The Hippo (Hpo) pathway com-
prises two kinase/adaptor complexes and a transcription
factor whose phosphorylation status controls its sub-cel-
lular localization. In Drosophila, the Hippo/Salvador
(Hpo/Sav) complex can phosphorylate and activate
WARTS (Wts) [12]. In turn, the (Wts/Mats) complex phos-
phorylates Yorkie, thereby maintaining it into the cyto-
plasm [13,14]. Inactivating mutations in hpo, sav, mats
and wtz or overexpression of yki produce similar pheno-
types such as increased cell proliferation, and diminished
apoptosis, as well as tissue overgrowth (reviewed in [1]).
Mammals share a similar pathway whereby the Mst2/
WW45 phosphorylates LATS1 [15], and the LATS1/Mob1
complex phosphorylates YAP1 to keep it in the cytoplasm
[13,16].
LATS1 was localized to centrosomes in interphase cells
but associated with the mitotic apparatus during mitosis
[17]. The fraction of LATS1 proteins present at the spindle
pole bodies during mitosis was shown to be phosphor-
ylated by cyclin B/Cdc2 [18]. LATS1 also associated with
zyxin on the mitotic apparatus [19], and colocalized with,
and inhibited the activity of, LIMK1 at the actomyosin
contractile ring during cytokinesis [20]. These findings
provided convincing evidence that LATS1 plays a role in
mitosis, however, there are conflicting data as to whether
Lats1 inhibits or stimulates progression through mitosis.
Overexpression of human LATS1 in MEF cells and human
tumor cell lines caused the inhibition of Cdc2 kinase
activity and this was associated with cell cycle arrest in G2/
M or apoptosis [5,21,22]. On the other hand, LATS1 was
found to stimulate cytokinesis by negatively regulating
LIMK1 and actin polymerization [20]. Moreover, LATS1
belongs to the nuclear Dbf2-related (NDR) family of pro-
tein kinases which are involved in cell cycle control in
yeast [23]. Indeed, LATS1 forms with MOB1 a complex
that localizes at the centrosomes and midbody, and over-
expression of LATS1 allowed cells to overcome the spindle
checkpoint, whereas siRNA against LATS1 or Mob1A
extended telophase, but not other phases of mitosis [24].
These results led the authors to propose that LATS1 is a
component of the mammalian mitotic exit network. In
this model, the previously described ability of LATS1 to
arrest cells in G2 could be explained if the excessively high
expression of LATS1 caused the premature inactivation of
Cdc2 and, as a consequence, prevented entry into mitosis.
CUX1 (cut homeobox 1) proteins are a family of tran-
scription factors present in all metazoans and involved in
the control of many cellular processes including determi-
nation of cell identity, cell cycle progression, cell-cell com-
munication and cell motility (reviewed in [25,26]). At
least three CUX1 protein isoforms have been described:
p200, p110 and p75. The full-length protein, p200 CUX1,
makes a rapid but unstable interaction with DNA and is
responsible for the CCAAT-displacement activity that has
been reported in early studies [27-29]. A shorter isoform,
p110 CUX1, is generated as a result of proteolytic process-
ing that does not takes place until the end of the G1 phase
in normal cells but becomes constitutive in many trans-
formed cells [30-32]. A third isoform, p75 CUX1, is gen-
erated from a shorter mRNA that is initiated within intron
20 and whose expression is restricted to certain cell-types
and was found to be activated in some human breast
tumors and cancer cell lines [33]. The p75 and p110 iso-
forms are much less abundant than the full-length iso-
form, however, in contrast to p200 both CUX1 short
isoforms can make a stable interaction with DNA and,
depending on promoter-context, can function as tran-
scriptional repressor or activator [30,31,33-35]. Constitu-
tive expression of p110 CUX1 was shown to stimulate cell
proliferation by accelerating entry into S phase [36].
Elevated  CUX1  mRNA and protein expression was
reported in primary tumors and cancer cell lines of vari-
ous types [37-40]. A more detailed analysis revealed that
expression of any one of the short isoforms was increased
in some tumors and cancer cell lines. The steady-state
level of p110 CUX1 was found to be elevated in many
human uterine leiomyomas [40]. While proteolytic
processing of CUX1 is tightly regulated during the cellMolecular Cancer 2009, 8:60 http://www.molecular-cancer.com/content/8/1/60
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cycle in normal cells, it is constitutive in many trans-
formed cells as a result of increased expression of nuclear
cathepsin L [30,32]. The intron 20-mRNA and p75 iso-
form was found to be aberrantly expressed in some pri-
mary breast tumors and cancer cell lines [33]. To
investigate and compare the oncogenic potential of the 3
CUX1 isoforms, we used specific transgenesis to generate
mice carrying a p75, p110 or p200 CUX1 transgene under
the control of the mouse mammary tumor virus promoter
(MMTV) and integrated into the hypoxanthine phos-
phoribosyltransferase (hprt) locus. In mixed genetic back-
grounds, many virgin p75 CUX1 mice succumbed to
myeloproliferative-disease (MPD)-like myeloid leuke-
mias [41]. In the FVB genetic background, multiparous
transgenic mice carrying a p75 or p110 CUX1 transgene
developed malignancies in the mammary gland and other
tissues, with a penetrance of approximately 50% [42].
Overall, these results demonstrated the oncogenic poten-
tial of p110 and p75 CUX1.
To identify targets of CUX1 that are involved in cell cycle
progression, we recently performed genome-wide loca-
tion analysis using a promoter microarray and 8 cell lines
of various cell-types [35]. Functional classes that were
over-represented among targets included genes involved
in mitosis and DNA replication initiation [35]. Expression
of DNA replication targets was increased in cells over-
expressing p110 CUX1, and was reduced following CUX1
knockdown. In contrast to the effect observed on most tar-
get genes, the p21CIP1 and cyclin H genes were repressed
by p110 CUX1 [35,43]. The promoter-specific repression
or activation of target promoters was confirmed in
reporter assays [35]. One putative target that was identi-
fied in all location arrays is the Lats1 gene. In the present
study, we performed experiments to verify whether Lats1
is a direct target of CUX1 and we investigated the regula-
tory effect of CUX1 on Lats1. We found that p110 and p75
CUX1 can stimulate the transcription of Lats1  both in
reporter assays and in cell lines stably expressing p110 or
p75 CUX1. Moreover, Lats1 expression was consistently
elevated in tumors of various tissue-types that develop in
p110 or p75 CUX1 transgenic mice.
Results
Lats1 Is Identified As a Putative Target of CUX1 in Cells of 
Various Tissue Types
Genome location analysis using a promoter array was pre-
viously performed in triplicate using chromatin from 8
human cell lines of various cell types: breast tumor
(Hs578T), cervical carcinoma (HeLa), kidney epithelial
(HEK293), myeloid leukemia (K562, HEL), and B cell
lymphoma (Ramos, U266, RPMI8266) ([35] and supple-
mental data therein). We utilized a genomic DNA micro-
array containing the region spanning 800 bp upstream
and 200 bp downstream of transcription start sites of
18,660 human genes [44]. Strikingly, the Lats1 gene was
identified as a putative target in all cell lines tested. The p
values of the CUX1/Lats1 interaction observed in each cell
line are shown in Table 1. To confirm that CUX1 binds to
the promoter of the Lats1 gene, scanning ChIP was per-
formed using primer pairs from different regions of the
Lats1 locus and chromatin from Hs578T cells immuno-
precipitated with CUX1 antibodies. Our results showed
that CUX1 bound to the region immediately upstream of
the transcription start site and amplified by primer pairs A
and B (Fig. 1B, lanes 3 and 5). Note that this region was
included within the Lats1 promoter sequences present on
the promoter microarray (Fig. 1A, see thick line under the
map). A weaker interaction was also observed within the
first intron (Fig. 1B, lane 8). In contrast, no binding was
observed to distal sequences located further downstream
of the transcription start site (Fig. 1B, lanes 10 and 12).
Interestingly, sequences matching the ATCRAT consensus
binding site for the Cut repeat 3 and Cut homeodomain
composite DNA binding domain of CUX1 were found at
2 positions upstream of the transcription start site and at
one position within intron 1 (Fig. 1A, see black triangles
below the map) [45]. Using the primer pair A, binding of
CUX1 to the Lats1 immediate promoter was validated in
all cell lines (data not shown). Altogether, these results
demonstrate that CUX1 binds to the immediate Lats1 pro-
moter in cells of various tissue types.
The immediate promoter region of LATS1 is sufficient for 
the regulation by CUX1
We wanted to confirm whether the 1-Kbp LATS1 genomic
region present on the promoter microarray was sufficient
for transcriptional regulation by CUX1. The LATS1 pro-
moter sequences were introduced into a luciferase
reporter plasmid and luciferase activity was measured in
the presence of effector plasmids expressing either p200,
p110 or p75 CUX1. Previous studies have revealed that
the full-length CUX1 isoform, p200, functions as a tran-
scriptional repressor whereas the shorter CUX1 isoform,
p110 and p75, can function as repressors or activators
depending on promoter-context [30,34,35,43,46].
Expression was not significantly affected by p200 CUX1,
but was stimulated in the presence of either p110 or p75
CUX1 (Fig. 2B, left panel). Moreover, the fold-activation
by p110 CUX1 was proportional to the amount of effector
plasmid (Fig. 2B, right panel). We conclude that the
immediate promoter region of LATS1 is sufficient for its
regulation by p110 and p75 CUX1.
p110 and p75 CUX1 activate transcription of the 
endogenous Lats1 gene
We then verified the effect of CUX1 on the endogenous
Lats1 gene. First, we compared Lats1 mRNA expression in
mouse embryo fibroblasts (MEFs) derived from a cux1-/-
knockout mouse or a wild type littermate [36]. RT-PCRMolecular Cancer 2009, 8:60 http://www.molecular-cancer.com/content/8/1/60
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analysis using two dilutions of the mRNA preparations
showed that Lats1 expression was higher in wild type than
in cux1-/- MEFs (Fig. 3A). This result suggested that CUX1
is required for optimal expression of Lats1. Next, cux1-/-
MEFs were infected with a retroviral vector expressing
p110 CUX1 or with a control empty vector and we meas-
ured  Lats1  mRNA expression by quantitative real-time
PCR amplification. Lats1 mRNA expression was increased
on average 15-fold in cux1-/- MEF cells expressing p110
CUX1 (Fig. 3B). We then turned to cell lines that express
CUX1 and asked whether increasing the level of p110 or
p75 CUX1 would affect endogenous Lats1  expression.
Lats1  mRNA steady-state level was increased approxi-
mately 3-fold in Hs578T breast tumor cells that were
infected with the p110 CUX1 retroviral vector (Fig. 3B and
3C). Similarly, Lats1  expression was increased in the
MCF10A human mammary epithelial cell line following
infection with a retroviral vector expressing p75 (Fig. 3D).
Altogether, these results demonstrate that p110 and p75
CUX1 stimulate expression of the endogenous Lats1 gene.
Lats1 is over-expressed in tumors from CUX1 transgenic 
mice
Transgenic mice have been engineered to express p75 or
p110 CUX1 under the control of regulatory sequences
from the long terminal repeat of the Mouse Mammary
Tumor Virus (MMTV-LTR) [41]. To be able to compare the
two CUX1 isoforms, specific transgenesis was used to inte-
grate the transgene into the hypoxanthine phosphoribo-
syltransferase (hprt) locus [47]. In mixed genetic
backgrounds, many virgin p75 CUX1 mice succumbed to
myeloproliferative-disease (MPD)-like myeloid leuke-
mias [41]. In the FVB genetic background, multiparous
transgenic mice carrying a MMTV-p75 or MMTV-p110
CUX1 transgene developed malignancies primarily in the
mammary gland [42]. In addition to mammary tumors, a
small number of tumors were also detected in other tis-
sues. In particular, a number of sarcomas with features
resembling that of histiocytic sarcomas were observed in
the uterus and liver of several mice. An example of this
type of tumor is presented (Fig. 4). The uterus was grossly
enlarged (Fig. 4B), and a large number of histiocytic/den-
dritic cells were observed in sections taken from the uterus
and the liver (Fig. 4D and 4F). Overall, results from CUX1
transgenic mice indicate that overexpression of p110 or
p75 CUX1 can increases the incidence of cancer in various
cell types.
We analyzed Lats1  mRNA expression in 4 mammary
gland tumors, 2 uterine tumors and 3 spleens from mice
suffering from MLPD-like myeloid leukemias. In the case
of mammary tumors, RNA from an adjacent normal
mammary gland served as a control. In the case of uterine
tumors and diseased spleens, we used RNA from the cor-
responding normal tissue of a non transgenic littermate.
In all cases, Lats1  mRNA expression was increased in
tumors from CUX1 transgenic mice (Fig. 5A, B and 5C).
Overexpression of Lats1 in NMuMG mammary epithelial 
cells does not hinder cell cycle progression
Loss of Lats1 and its ortholog warts has been associated
with increased susceptibility to various types of cancers
[2,3,6]. This protective function of Lats1 against cancer
has been linked to its role in cell cycle progression during
mitosis. However, it is not clear from previous studies
whether overexpression of Lats1 would necessarily cause a
delay in cell cycle progression [21,24]. We therefore inves-
tigated cell cycle progression using non-transformed
NMuMG mouse mammary epithelial cells carrying a p110
CUX1 retroviral vector or the empty vector. As shown in
Fig. 6A, Lats1 expression was significantly higher in cells
carrying the p110 CUX1 retrovirus. Cells were synchro-
nized at the G1/S transition using the double thymidine
block procedure and then allowed to proceed through the
cell cycle. Samples taken at different times were stained
with propidium iodide and the cell cycle profile of cells
was analyzed by FACS analysis. This experiment was per-
formed independently three times and representative
results are presented (Fig. 6B). No delay in cell cycle pro-
gression was observed in cells over-expressing p110 CUX1
and  Lats1. In fact, cells of the p110 CUX1 population
reached the next G1 phase a little bit faster than the con-
Scanning ChIP analysis of the LATS1 locus using CUX1 anti- bodies Figure 1
Scanning ChIP analysis of the LATS1 locus using 
CUX1 antibodies. (A) Diagram of the LATS1 locus. Exons 
are numbered and the transcription start site is indicated by 
an arrow. The positions of primer pairs used in the analysis 
of chipped DNA are indicated by arrows above the map. 
Primer sequences are given in Materials & Methods. The 
positions of p110 and p75 CUX1 consensus binding sites 
(ATCRAT) are indicated by black triangles below the map. 
The thick line shows the genomic sequences present on the 
promoter microarray that was used in the location array 
analysis. (B) Chromatin from Hs578T cells was immunopre-
cipitated with the CUX1-861 antibody and analyzed by PCR 
amplification using primers specific for different regions of 
the LATS1 locus. Templates for the PCR reactions were 0.1% 
total input DNA (T) or ChIP-purified DNA (IP).
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trol vector-cells (Fig. 6B, see the 6-hour time point). We
conclude that higher expression of Lats1 does not slow
down progression through the S, G2 and mitosis phases
of the cell cycle.
Discussion
We have presented evidence demonstrating that the Lats1
gene is a transcriptional target of the CUX1 homeodo-
main protein. The Lats1 gene promoter region was identi-
fied in 8 of 8 genome-wide location arrays using CUX1-
associated chromatin from cell lines of various tissue
types (Table 1). Scanning ChIP analysis confirmed that
CUX1 binds to genomic sequences located immediately
upstream of the Lats1  transcription start site and, to a
lesser extent, to sequences within the first intron (Fig. 1).
The 5' flanking sequences were found to include two
CUX1 consensus binding sites, and the intron 1 sequences
included one such binding site (Fig. 1). A luciferase
reporter plasmid containing the immediate promoter
region of Lats1 was activated by p110 and p75 CUX1 (Fig.
2). Comparison of Lats1 steady state mRNA levels in cux1-
/- and cux1+/+ MEFs indicated that CUX1 is required for
Lats1 expression (Fig. 3A). Indeed, Lats1 expression was
stimulated up to 15-fold upon the reintroduction of p110
CUX1 in cux1-/- MEFs (Fig. 3B). Interestingly, in cell lines
that are not defective for CUX1, Lats1 expression was also
stimulated following the infection of cells with a retrovi-
rus expressing p110 or p75 CUX1 (Fig. 3B, C and 3D and
6A). As CUX1 was shown to participate in the transcrip-
tional activation of several genes that play a role in DNA
replication and mitosis, the regulation of Lats1 by CUX1
is consistent with the function of CUX1 in cell cycle pro-
gression [35]. CUX1 DNA binding and transcriptional
activities were previously shown to be activated at the end
Table 1: Lats1 is identified as a putative target of p110 CUX1 in 8 
cell lines
HEL 4.3E-11
K562 3.5E-9
U266 1.5E-3
Ramos 4.0E-4
Hs578T 3.5E-7
HeLa 1.6E-4
293 1.5E-8
RPMI 5.7E-6
Genome-wide location analysis was performed using a panel of 8 
human cell lines of various cell types: breast tumor (Hs578T), cervical 
carcinoma (HeLa), kidney epithelial (HEK293), myeloid leukemia 
(K562, HEL), and B cell lymphoma (Ramos, U266, RPMI8266). For 
each cell line, hybridization experiments were done in triplicate using 
three independent ChAP-enriched and input DNA samples (8 cell 
lines × 3 hybridizations = 24). ChAP-enriched DNA regions 
associated with p110 CUX1 were purified and labeled with Cy5 dye. 
Equal amounts of Cy5-labeled ChAP products and Cy3-labeled input 
DNA samples were co-hybridized onto a human genomic DNA 
microarray containing the region spanning 800 bp upstream and 200 
bp downstream of transcription start sites of 18,660 human genes. P 
values observed for the Lats1 promoter are shown. The data is taken 
from [35]. CDP/Cux p110 and p75 isoforms increases Lats1 transcrip- tion activity in reporter assays Figure 2
CDP/Cux p110 and p75 isoforms increases Lats1 
transcription activity in reporter assays. (A) Diagram of 
the LATS1 reporter construct. The promoter region of the 
LATS1 gene, from nt -1463 to +310, was cloned into a luci-
ferase reporter plasmid. (B) Hs578T cells were transfected 
with the LATS1 reporter plasmid together with vectors 
expressing either p200, p110 or p75 CUX1 or with an empty 
vector. 24 hours after transfection, whole cell extracts were 
prepared and processed to measure luciferase activity. The 
results are expressed as relative light units (RLU), normalized 
to β-galactosidase activity from an internal control and the 
standard deviation of 3 transfections is shown. (C) NIH3T3 
cells were transfected with the LATS1 reporter plasmid 
together with increasing amount of a vector expressing p110 
CUX1 or with an empty vector. Samples were processed as 
detailed in (B).
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of the G1 phase [30,31,43]. Once activated, CUX1 coop-
erates with other factors to activate the transcription of
genes that are required for the replication of DNA and
later the completion of cell division [34-36,46]. Constitu-
tive expression of p110 CUX1 was indeed shown to accel-
erate entry into S phase without apparent deleterious
consequences [36]. Cells continued to progress unabated
through the cell cycle and proliferated faster and reached
a higher density at saturation than control cells [36].
Transgenic mice expressing p75 or p110 CUX1 developed
tumors in various tissues including the hematopoietic sys-
tem, the mammary gland and the uterus. In mammary
tumors, in MLPD-like leukemias and in uterine tumors,
Lats1  mRNA expression was consistently elevated in
tumors as compared to control normal tissues (Fig. 5).
Although this finding is consistent with the fact that
CUX1 activates Lats1 transcription, there is an apparent
discrepancy between the elevated expression of Lats1 in
tumors from transgenic mice and the purported role of
LATS1 as a tumor suppressor. Obviously, tumors can grow
in spite of elevated LATS1 expression. Moreover, when cell
cycle progression was monitored in tissue culture, we did
not observe any delay in cells that over-expressed both
p110 CUX1 and Lats1 (Fig. 6). In this respect, our results
are in agreement with a previous study showing that a
moderate increase (from 2 to 5-fold) in Lats1 expression
did not hinder cell cycle progression [24]. In contrast, the
introduction of a Lats1  gene into cells by Adenovirus-
mediated gene transfer caused a block at the G2/M transi-
tion [21]. We favor the interpretation proposed by Bothos
et al. suggesting that the extremely high concentration of
Lats1 that was achieved with an Adenovirus vector may
have caused the premature inhibition of cyclin B/Cdk1 at
the end of the G2 phase, instead of during telophase as in
normal cells [21,24].
There is solid genetic evidence in Drosophila and mice to
establish the role of LATS1 as a tumor suppressor. Loss-of-
function of warts in Drosophila and of Lats1 in the mouse
has been shown to increase the susceptibility to cancers in
various tissues [3,4,6]. Yet, the role of LATS1 as a tumor
suppressor does not necessarily mean that elevated
expression of LATS1 would hinder cell proliferation and
prevent tumor growth, as demonstrated here and in
another study [24]. Moreover, genetic analysis in human
tumors did not provide a compelling case for the inactiva-
tion of LATS1 in human cancers. While hypermethylation
of the LATS1 promoter has been reported [9-11], these
cases are not common and so far no inactivating mutation
has been documented. Interestingly, a search of the
Oncomine database revealed only two studies where a dif-
ference in LATS1 expression was observed between nor-
mal and cancer samples [48]. In both cases, cervical
Endogenous Lats1 expression is regulated by CUX1 Figure 3
Endogenous Lats1 expression is regulated by CUX1. 
RNA was prepared from mouse embryo fibroblasts and vari-
ous cell lines expressing either p110 or p75 CUX1 or carry-
ing an empty vector, as indicated. Lats1 mRNA expression 
was analyzed by RT-PCR using GAPDH as a control. Ampli-
cons were resolved by agarose gel electrophoresis (A-D). 
(A) Mouse embryo fibroblasts (MEFs) derived from cux1-/- 
and cux1+/+ mice. (B) Lats1 mRNA expression was measured 
by quantitative real-time PCR in cux1-/- MEF and Hs578T 
human breast tumor cells expressing p110 CUX1 or carrying 
an empty vector. GAPDH levels were used to normalize the 
samples. The values are the mean of three measurements 
and error bars represent standard deviation. (C) MCF10A 
human mammary epithelial cells (D) NMuMG mouse mam-
mary epithelial cells.
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cancers and basal-like breast cancers, LATS1 expression
was higher in the tumor than in the normal tissue [49,50].
Conclusion
In summary, while loss-of-function of Lats1 can predis-
pose to cancer, there is compelling evidence both from
transgenic mouse models and from human cancers that
Lats1 can be overexpressed in tumors. Lats1 is not unique
in this respect. Indeed, many genes that play a role in the
mitotic checkpoint were found to be either over-expressed
or inactivated in various cancers [51,52]. While the mech-
anistic details remain to be deciphered, the overall picture
that has emerged suggests that the mitotic regulatory net-
work can be perturbed through both the elevated or
decreased expression of some of its components
(reviewed in [52]).
Methods
Cell Culture
NIH3T3, Hs578T and NMuMG cells were cultured in Dul-
becco's Modified Minimum Essential Medium (DMEM)
supplemented with penicillin-streptomycin, glutamine,
and 10% fetal bovine serum (FBS) (Gibco); 10 μg/ml
insulin was added to the medium for NMuMG cells.
Cell synchronization and Fluorescence -activated cell 
sorting (FACS) analysis
NMuMG cells (100,000 cell/plate) were cultured in
DMEM medium supplemented with 10% FBS and 10 μg/
ml insulin. Synchronization in G1/S was performed using
the double thymidine procedure [53]. Cells were cultured
overnight in DMEM plus 10% FBS supplemented with 2
mM thymidine, washed the next day, cultured for 10
hours in DMEM plus 10% FBS and finally further incu-
bated overnight in the presence of 2 mM thymidine (Thy-
midine 0 h). To allow cells to progress in the cell cycle, the
medium was replaced with DMEM plus 10% FBS and cells
were harvested at different times thereafter. FACS analysis
was performed as previously described [43].
Chromatin Immunoprecipitation
We used 4 × 108 Hs578T cells for the chromatin immuno-
precipitation with anti CUX1 antibodies 861 and 1300,
using our previously described protocol [34,35]. Chroma-
tin affinity purification (ChAP) was performed for the
genome-wide location analysis. A complete protocol for
ChAP as well as an excel file detailing the results in 8 cell
lines are provided in the supplemental data of Harada et
al., 2008 [35]. For scanning ChiP, the following primers
were used: primer that amplify region A, 5'-TTGGGTTT-
GATGTATAAGGTACGG-3' and 5'-GTGCTGGGATTACAG
GCGTGAGAC-3'; region B, 5'-TCTTATCTGTCAACCG
CATCCGTAGA-3' and 5'-GGACCGTACCTTATACATCA
AACCCAACGA-3'; region C, 5'-AAAGTGTTAATTT-
GGGTTGAA-3' and 5'-CATGAAGATACAGCGTTGCTT-3';
region D, 5'-AAAGTGTTAATTTGGGTTGAA-3' and 5'-
CATGAAGATACAGCGTTGCTT-3'; region E, 5'-CAGGCT-
GGAATTGGG TATCTTATT-3'and 5'-ATG GGAAACT-
GGAGGTGGGCTAAC-3'
Luciferase construct and luciferase assay
LATS1 5' flanking sequences were amplified from Hs578T
genomic DNA using the following primers 5'-ATCATTC-
CACCTCTGCTTTCCCTGC-3' and 5'-TGGGGCAGAGCG-
GGGAGACG-3' which amplifies a 1775 base pair
fragment that include 1464 base pair upstream of the
transcription start site, start site and 311 base pairs of exon
1. The PCR product was cloned into XhoI and HindIII site
of pGL3 (Promega). NIH3T3 cells and Hs578T cells were
transiently transfected with CUX1 p200, p110 (831–
1505) or p75 (1062–1505) and pGL3-Lats1. We utilized 2
different vectors for the CUX1 constructs pTriEx1.1
(Novagen) and pXJ42 [54], both revealing similar results.
Luciferase assay was performed as previously described
[30].
RNA extraction, reverse transcriptase PCR (RT-PCR) and 
real-time PCR
RNA was extracted using TRIzol reagent (Invitrogen) fol-
lowed by cDNA preparation using the superscript II RNase
H-reverse transcriptase kit (Invitrogen) as provided in the
p110 CUX1 transgenic mice develop uterine histiocytic sar- comas with liver infiltration Figure 4
p110 CUX1 transgenic mice develop uterine histio-
cytic sarcomas with liver infiltration. (A, B) Pictures of 
the uterus from wild-type (A) and p110 CUX1 transgenic (B) 
mice. (C-F) H&E staining of the uterus (C, D) and liver (E, F) 
from wild-type and p110 CUX1 transgenic mice respectively.
AB
Wild-type p110 CUX1 
CD
EF
Uterus
Uterus
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manufacturer manual. Real-time PCR was performed on a
LightCycler instrument (Roche) using the FastStart DNA
Master SYBR Green kit (Roche). The following oligonucle-
otides were used for the amplification of mouse Lats1
cDNA: 5'-TAGAATGGGCATCTTTCCTGA-3' and 5'-
TGCTATCTTGCCGTGGGT-3' (Fig. 3A and 3D), and 5'-
AATAGGAGCGTTTGGTGAAGTC-3' and 5'-TGTGTC-
CATCTGAAGCCAGTG-3' (Fig. 5). Human LATS1 cDNA:
Lats1 is overexpressed in tumors from p75 and p110 CUX1  transgenic mice Figure 5
Lats1 is overexpressed in tumors from p75 and p110 
CUX1 transgenic mice. RNA was prepared from tumors 
and either adjacent normal tissue (mammary gland) or equiv-
alent normal tissue from a non-transgenic littermate. Lats1 
mRNA expression was analyzed by RT-PCR using GAPDH 
or β-actin as a control, as indicated. (A) Mammary gland 
tumors and adjacent normal mammary gland. (B) Uterine 
tumors and normal uterus from a non-transgenic littermate. 
(C) Enlarged and normal spleens from p75 CUX1 transgenic 
mice and non-transgenic littermates, respectively.
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Overexpression of Lats1 in NMuMG epithelial cells does not  hinder cell cycle progression Figure 6
Overexpression of Lats1 in NMuMG epithelial cells 
does not hinder cell cycle progression. (A) RNA was 
prepared from NMuMG mouse epithelial cells expressing 
p110 CUX1 or carrying an empty vector. Lats1 mRNA 
expression was analyzed by RT-PCR using GAPDH as a con-
trol. (B) Cells were synchronized at the G1/S transition using 
the double thymidine block procedure, and then released 
from the block and allowed to progress in the cell cycle. 
Nuclei were stained with propidium iodide and DNA con-
tent was determined by fluorescence-activated cell sorting 
(FACS) analysis. Cell cycle profiles were analyzed using the 
Watson model and the FlowJo™ software. The numbers 
below the FACS profiles indicate the percentage of cells with 
2N DNA content (G0/G1 cells), between 2N and 4N DNA 
content (S phase cells) and 4N DNA content (G2/M cells).
(A)
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5'-ACCGCTTCAAATGTGACTGTGATGCCACCT-3' and 5'-
CTTCCTTGGGCAAGCTTGGCTGATCCTCT-3'.
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